Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takako Inoue

Showing results (101-110 of 144) with videos related to

Pageof 15
Sort By:
Cancer Genetics|April 26, 2021
Late recurrence of lung adenocarcinoma harboring EGFR exon 20 insertion (A763_Y764insFQEA) mutation successfully treated with osimertinibKei Kunimasa, Kazumi Nishino, Yoji Kukita, et al.
JACC. Cardiooncology|August 16, 2021
Cardiac Adverse Events in <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer Treated With OsimertinibKei Kunimasa, Risa Kamada, Toru Oka, et al.
Plos One|February 19, 2015
Validation of cross-genotype neutralization by hepatitis B virus-specific monoclonal antibodies by in vitro and in vivo infectionSusumu Hamada-Tsutsumi, Etsuko Iio, Tsunamasa Watanabe, et al.
Cancer|September 8, 2018
Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study)Akito Hata, Nobuyuki Katakami, Reiko Kaji, et al.
Thoracic Cancer|February 24, 2018
HER3 expression is enhanced during progression of lung adenocarcinoma without EGFR mutation from stage 0 to IA1Toru Kumagai, Yasuhiko Tomita, Shin-Ichi Nakatsuka, et al.
Anticancer Research|September 6, 2017
Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of Interstitial Lung Disease and Progression-free Survival of Patients with Pre-treated Advanced Non-small Cell Lung CancerAkihiro Tamiya, Motohiro Tamiya, Kenji Nakahama, et al.
Molecular and Clinical Oncology|March 8, 2021
Efficacy and safety of Infliximab for steroid-resistant immune-related adverse events: A retrospective studyYukio Kadokawa, Mari Takagi, Tomoe Yoshida, et al.
Journal of Gastroenterology|April 28, 2022
Clinical usefulness of a novel high-sensitivity hepatitis B core-related antigen assay to determine the initiation of treatment for HBV reactivationTakanori Suzuki, Takako Inoue, Kentaro Matsuura, et al.
Anticancer Research|July 3, 2019
Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?Motohiro Tamiya, Akihiro Tamiya, Hidekazu Suzuki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|February 24, 2022
Management of hepatitis B virus (HBV) reactivation in patients with resolved HBV infection based on a highly sensitive HB core-related antigen assayShinya Hagiwara, Shigeru Kusumoto, Takako Inoue, et al.
Pageof 15

Showing results (101-110 of 144) with videos related to

Sort By:
Pageof 15
Cancer Genetics|April 26, 2021
Late recurrence of lung adenocarcinoma harboring EGFR exon 20 insertion (A763_Y764insFQEA) mutation successfully treated with osimertinibKei Kunimasa, Kazumi Nishino, Yoji Kukita, et al.
JACC. Cardiooncology|August 16, 2021
Cardiac Adverse Events in <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer Treated With OsimertinibKei Kunimasa, Risa Kamada, Toru Oka, et al.
Plos One|February 19, 2015
Validation of cross-genotype neutralization by hepatitis B virus-specific monoclonal antibodies by in vitro and in vivo infectionSusumu Hamada-Tsutsumi, Etsuko Iio, Tsunamasa Watanabe, et al.
Cancer|September 8, 2018
Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study)Akito Hata, Nobuyuki Katakami, Reiko Kaji, et al.
Thoracic Cancer|February 24, 2018
HER3 expression is enhanced during progression of lung adenocarcinoma without EGFR mutation from stage 0 to IA1Toru Kumagai, Yasuhiko Tomita, Shin-Ichi Nakatsuka, et al.
Anticancer Research|September 6, 2017
Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of Interstitial Lung Disease and Progression-free Survival of Patients with Pre-treated Advanced Non-small Cell Lung CancerAkihiro Tamiya, Motohiro Tamiya, Kenji Nakahama, et al.
Molecular and Clinical Oncology|March 8, 2021
Efficacy and safety of Infliximab for steroid-resistant immune-related adverse events: A retrospective studyYukio Kadokawa, Mari Takagi, Tomoe Yoshida, et al.
Journal of Gastroenterology|April 28, 2022
Clinical usefulness of a novel high-sensitivity hepatitis B core-related antigen assay to determine the initiation of treatment for HBV reactivationTakanori Suzuki, Takako Inoue, Kentaro Matsuura, et al.
Anticancer Research|July 3, 2019
Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?Motohiro Tamiya, Akihiro Tamiya, Hidekazu Suzuki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|February 24, 2022
Management of hepatitis B virus (HBV) reactivation in patients with resolved HBV infection based on a highly sensitive HB core-related antigen assayShinya Hagiwara, Shigeru Kusumoto, Takako Inoue, et al.
Pageof 15